Methods for improving respiratory system health and increasing the concentration of hypothiocyanate ion in vertebrate lungs
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11426428-B2
Publication Date
2022-08-30
Expiration Date
Abstract
The present disclosure relates to methods and devices to improve respiratory system health, increase resistance to infection, and increase the hypothiocyanate ion in mammalian lungs. The methods generally comprise: generating a Hydrogen Peroxide Gas that is non-hydrated and free of ozone, and directing the gas comprising primarily Hydrogen Peroxide Gas into an environment and exposing a subject to the environment such that the Hydrogen Peroxide Gas acts to the increase of the hypothiocyanate ion in mammalian lungs.
Core Innovation
The invention provides methods for treating a respiratory illness in a human subject using an enclosed space for treatment. The enclosed space includes purified hydrogen peroxide gas (PHPG) that is substantially free of hydration and ozone, at a final concentration of at least 0.01 parts per million (ppm). The subject is treated by exposing the subject to the environment for at least one period of time to provide a therapeutic amount of PHPG.
The invention addresses reducing the severity of a respiratory infection or reducing the duration of a respiratory infection. The human subject has a respiratory infection caused by an influenza virus, a severe acute respiratory syndrome (SARS) virus, a Middle East Respiratory Syndrome (MERS) virus, or a respiratory syncytial virus (RSV). The described mechanism links inhaled hydrogen peroxide gas (H2O2) to hypothiocyanate ion (OSCN−) and hypothiocyanous acid (HOSCN) production via lung lactoperoxidase acting on thiocyanate ion (SCN−).
The invention also describes that PHPG exposure in habitable or enclosed environments is associated with improved respiratory outcomes, including reduced infection incidence, reduced severity and duration of respiratory illness, improved lung function, and reduced transmission. The described context includes home use and team facility deployment, and includes a case involving improved resistance after mustard-agent exposure.
Claims Coverage
The partial content includes one independent claim covering a PHPG-enclosed-space treatment method for human respiratory infections, with dependents that refine the therapeutic endpoint, exposure time, and concentration thresholds. The independent claim includes treating to reduce severity or duration for listed viruses.
Enclosed treatment space with non-hydrated, ozone-free PHPG at at least 0.01 ppm
Providing an enclosed space for treatment comprising purified hydrogen peroxide gas (PHPG) that is substantially free of hydration and ozone at a final concentration of at least 0.01 parts per million (ppm).
Therapeutic exposure to deliver PHPG to reduce severity or duration
Treating the human subject in need by exposing the subject to said environment for at least one period of time to provide a therapeutic amount of PHPG, wherein said treating reduces the severity of a respiratory infection or reduces the duration of a respiratory infection.
Use for human influenza, SARS, MERS, or RSV infected respiratory infection
The subject in need is a human infected by an influenza virus, a severe acute respiratory syndrome (SARS) virus, a Middle East Respiratory Syndrome (MERS) virus, or a respiratory syncytial virus (RSV), wherein the subject has a respiratory infection.
Reducing severity by reducing respiratory symptoms
Reducing the severity of a respiratory infection by reducing one or more listed respiratory symptoms, including nasal congestion, runny nose (rhinorrhea), nasal discharge, nasal breathing, sneezing, sore or scratchy throat, painful swallowing (odynophagia), cough, malaise, and fever.
Reducing duration of respiratory infection
Treating includes reducing the duration of a respiratory infection.
Minimum period exposure over a 7-day period
The specified period time is at least 8 hours over a 7-day period.
Minimum total exposure time
The method is performed with a total exposure time of at least 1 hour.
Higher PHPG concentration threshold
The method is performed in an environment that includes PHPG at a final concentration of at least 0.1 ppm.
Across the independent claim and its dependents, the coverage centers on using an enclosed treatment space containing substantially non-hydrated, ozone-free PHPG at at least 0.01 ppm, delivered by therapeutic exposure for at least one period of time to reduce respiratory infection severity or duration, specifically for human influenza, SARS, MERS, or RSV infections; dependents refine symptom-level severity reduction, duration reduction, exposure schedule, total exposure time, and PHPG concentration.
Stated Advantages
Reduces the severity of a respiratory infection.
Reduces the duration of a respiratory infection.
Reduces one or more respiratory symptoms associated with infection, including nasal congestion, runny nose (rhinorrhea), nasal discharge, nasal breathing, sneezing, sore or scratchy throat, painful swallowing (odynophagia), cough, malaise, and fever.
Reduced infection incidence, improved lung function, and reduced transmission are described in habitable or enclosed environments.
Reduced missed training days are described for team facility deployment.
Documented Applications
Treating human respiratory infections infected by influenza virus, SARS virus, MERS virus, or RSV using PHPG in an enclosed space for treatment.
Home use and habitable or enclosed environment use associated with reduced infection incidence and reduced severity or duration of respiratory illness.
Team facility deployment associated with reduced missed training days.
A case described as improved resistance after mustard-agent exposure.
Interested in licensing this patent?